Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial

Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), potently and selectively inhibits EGFR-TKI-sensitizing and EGFR T790M resistance mutations. This analysis evaluates acquired resistance mechanisms to second-line osimertinib (n = 78) in patients with EGFR T790M ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Chmielecki, Juliann, Mok, Tony, Wu, Yi-Long, Han, Ji-Youn, Ahn, Myung-Ju, Ramalingam, Suresh S., John, Thomas, Okamoto, Isamu, Yang, James Chih-Hsin, Shepherd, Frances A., Bulusu, Krishna C., Laus, Gianluca, Collins, Barbara, Barrett, J. Carl, Hartmaier, Ryan J., Papadimitrakopoulou, Vassiliki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971022/
https://www.ncbi.nlm.nih.gov/pubmed/36849516
http://dx.doi.org/10.1038/s41467-023-35962-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971022/
https://www.ncbi.nlm.nih.gov/pubmed/36849516
http://dx.doi.org/10.1038/s41467-023-35962-x

Ejemplares similares